Abstract:

Objective:Haematuria, which is the most common presenting symptom in bladder cancer (BCa), may also occur with the effect of some medications. The aim of this study was to evaluate the role of antiplatelet (AP) drugs in the diagnosis of BCa. Material and methods:Patients who applied to our urology clinic between January 2013 and December 2018 and underwent transurethral resections (TURs) for primary BCa were reviewed retrospectively. Patients were divided into 2 groups according to AP drug use (group 1: no AP therapy, group 2: recieving AP therapy). The groups were compared in terms of demographic data, complaint of admission, smoking status, tumor size, multifocality, pathologic stage and grade, and BCa risk group. Results:A total of 290 patients, 233 in Group 1 and 57 in Group 2, were included in the study. The mean age of the patients was 68.69 ± 9.48 years and 246 of (84.8%) patients were male. There was no statistically significant difference between groups in terms of age, sex, presenting symptom, smoking status, tumor size, multifocality, pathological stage and grade and BCa risk groups. Conclusion:According to our results, AP drug use in BCa was found to have no effect on pathologic results, tumor size, multifocality and presenting symptom at the first diagnosis and can not be conclude that cause early or delayed diagnosis in BCa.

Keywords: